RxDoctor Payments Data

Yulong Yang, MD

Internal Medicine · Fort Lee, NJNPI 1013392919

Payments from drug & device makers

$1,953in general payments, 2019–2025

Across 129 payments — averaging $15.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$574
  • Amgen$406
  • AstraZeneca$285
  • Boehringer Ingelheim$178
  • AbbVie$127
  • Lilly USA, LLC$86
  • plus $298 from 8 others

What the payments were for

  • Food & beverage$1,93699%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,953 in reported general payments places this provider in the 75th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$138,180
Medicare patients
144
Services billed
2,021

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol101$127,854
ProliaDenosumab36$60,631
Evenity (2 Syringes)Romosozumab-Aqqg15$45,705
JardianceEmpagliflozin26$34,080
EliquisApixaban12$21,133
JanuviaSitagliptin Phosphate12$14,504
VascepaIcosapent Ethyl17$12,163
Atorvastatin Calcium537$3,460
Losartan Potassium296$1,796
Amlodipine Besylate362$1,524
Celecoxib39$1,431
Pantoprazole Sodium104$898
Metformin Hcl145$768
Levothyroxine Sodium106$731
Tamsulosin Hcl77$730

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$285$127,854101 claims
AmgenProlia, Evenity (2 Syringes)$406$106,33551 claims
Boehringer IngelheimJardiance$178$34,08026 claims
PfizerEliquis$45$21,13312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Fort Lee

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →